Search for a trial

A SINGLE-CENTER, SINGLE-DOSE, OPEN-LABEL, THREE-WAY-CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS OF THE HP-3070 PATCH (ASENAPINE TRANSDERMAL DRUG DELIVERY SYSTEM) FOLLOWING 24-HOUR APPLICATION COMPARED TO SINGLE-DOSE SYCREST® 5 MG (ASENAPINE, SUBLINGUAL) IN HEALTHY ADULT MALE AND FEMALE SUBJECTS

The main purpose of the study is to investigate whether the transdermal patch system HP-3070 shows blood concentrations of asenapine that make this route of administration suitable for clinical use. The transdermal route of administration is likely…